



**SZABO
SCANDIC**

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic



Cripto (h2): 293T Lysate: sc-370943



BACKGROUND

teratocarcinoma-derived growth factor (TDGF)-1 gene encodes a protein known as cripto-1 (Cripto). Cripto is first expressed in the forming mesoderm during gastrulation but later in development the expression is restricted to the truncus arteriosus of the developing heart. This suggests that Cripto mediates the progression of epiblastic cells that give rise to the mesoderm. In the adult animal it is expressed at low levels in the spleen, heart, lung and brain. Cripto overexpression is characteristic of human gastric and colorectal carcinomas.

REFERENCES

1. Dono, R., et al. 1993. The murine cripto gene: expression during mesoderm induction and early heart morphogenesis. *Development* 118: 1157-1168.
2. Brandt, R., et al. 1994. Identification and biological characterization of an epidermal growth factor-related protein: cripto-1. *J. Biol. Chem.* 269: 17320-17328.
3. Baldassarre, G., et al. 2001. A truncated form of teratocarcinoma-derived growth factor-1 (cripto-1) mRNA expressed in human colon carcinoma cell lines and tumors. *Tumour Biol.* 22: 286-293.
4. Adamson, E.D., et al. 2002. Cripto: a tumor growth factor and more. *J. Cell. Physiol.* 190: 267-278.
5. Parisi, S., et al. 2003. Nodal-dependent Cripto signaling promotes cardiomyogenesis and redirects the neural fate of embryonic stem cells. *J. Cell. Biol.* 163: 303-314.
6. Shen, M.M. 2003. Decrypting the role of Cripto in tumorigenesis. *J. Clin. Invest.* 112: 500-502.
7. Gray, P.C., et al. 2003. Cripto forms a complex with Activin and type II Activin receptors and can block Activin signaling. *Proc. Natl. Acad. Sci. USA* 100: 5193-5198.
8. Xing, P.X., et al. 2004. Cripto: a novel target for antibody-based cancer immunotherapy. *Cancer Res.* 64: 4018-4023.

CHROMOSOMAL LOCATION

Genetic locus: TDGF1 (human) mapping to 3p21.31.

PRODUCT

Cripto (h2): 293T Lysate represents a lysate of human Cripto transfected 293T cells and is provided as 100 µg protein in 200 µl SDS-PAGE buffer.

APPLICATIONS

Cripto (h2): 293T Lysate is suitable as a Western Blotting positive control for human reactive Cripto antibodies. Recommended use: 10-20 µl per lane.

Control 293T Lysate: sc-117752 is available as a Western Blotting negative control lysate derived from non-transfected 293T cells.

STORAGE

Store at -20° C. Repeated freezing and thawing should be minimized. Sample vial should be boiled once prior to use. Non-hazardous. No MSDS required.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

PROTOCOLS

See our web site at www.scbt.com for detailed protocols and support products.